大剂量阿托伐他汀对急性冠状动脉综合征患者血清抗氧化能力的影响

目的探讨大剂量阿托伐他汀对急性冠状动脉综合征患者血清抗氧化能力的影响。方法168例急性冠状动脉综合征患者随机分为大剂量阿托伐他汀治疗组和小剂量阿托伐他汀治疗组,分别检测治疗前、治疗1周和治疗2周后血清超氧化物歧化酶、谷胱甘肽过氧化物酶和丙二醛的含量;同时选择健康体检者50例作为正常对照组。结果急性冠状动脉综合征患者血清超氧化物歧化酶和谷胱甘肽过氧化物酶含量明显低于正常对照组(P<0.01),血清丙二醛含量明显高于对照组(P<0.01)。小剂量阿托伐他汀治疗组血清超氧化物歧化酶、谷胱甘肽过氧化物酶和丙二醛含量在阿托伐他汀治疗1周后无明显变化(P>0.05),治疗2周后血清超氧化物歧化酶和谷胱甘肽过氧化物酶含量开始升高(P<0.05),丙二醛开始下降(P<0.01)。大剂量阿托伐他汀治疗组在阿托伐他汀治疗1周时血清超氧化物歧化酶和谷胱甘肽过氧化物酶含量升高(P<0.05)、丙二醛含量明显降低(P<0.01),治疗2周后超氧化物歧化酶和谷胱甘肽过氧化物酶继续升高(P<0.05),丙二醛继续下降(P<0.01);且其血清超氧化物歧化酶和谷胱甘肽过氧化物酶含量升高幅度和丙二醛下降幅度均大于小剂量阿托伐他汀治疗组。结论短期大剂量阿托伐他汀能提高急性冠状动脉综合征患者血清的抗氧化能力。

The Effect of High Dose Atorvastatin on the Antioxidation Activity in Patients with Acute Coronary Syndrome

Aim To investigate the effects of high dose atorvastatin on the antioxidation activity in patients with acute coronary syndrone(ACS). Methods 168 patients with ACS were divided randomly into two groups patients.Patients in a group were treated with high dose atorvastatin(40 mg/d),and in another group with low dose atorvastatin(10 mg/d).Superoxide dismutase(SOD),GSHPx,malondialdehyde(MDA) measurment were taken before the treatment,on the 1 week and 2 week.50 healthy volunteers were assigned to the normal control group. Results SOD,GSHPx activity were lower significantly in patients with ACS compared with those of the nomal control subjects(83.24±21.45 ku/L and 80.53±19.67 ku/L vs 104.53±21.87 ku/L,1 327.7±426.5 ku/L and 1 341.2±396.8 ku/L vs 1 681.2±385.8 ku/L,p<0.01),and MDA was higher significantly in patients with ACS compared with those of the nomal control subjects(6.23±2.13 mmol/L and 6.02±1.89 mmol/L vs 3.52±2.09 mmol/L,p<0.01).After 1 week atorvastatin treatment,the SOD,GSHPx,MDA activity of the patients with high dose atorvastatin were improved significantly(91.56±23.64 ku/L vs 80.53±19.67 ku/L,1 483.3±402.3 ku/L vs 1 327.7±426.5 ku/L,p<0.05,4.57±2.37 mmol/L vs 6.23±2.13 mmol/L,p<0.01),which were much better in group high dose atorvastatin than those in group low dose atorvastatin(p<0.05). Conclusions The short-term treatment with high-dose atorvastatin could enhance the ability against superoxide injury in patients with ACS.